化疗和放疗对可切除性胃癌的临床治疗研究进展

基于各项Ⅲ期临床研究,近年来,术后化放疗、围手术期ECF方案（表柔比星、顺铂和氟尿嘧啶）化疗以及术后口服S-1辅助化疗分别成为了美国、欧洲和日本治疗可切除性胃癌的标准辅助治疗方式.2001年,美国西南肿瘤组（SWOG）报道的大型Ⅲ期随机临床试验（INT0116）结果,使得术后化放疗在美国成为可切除性胃癌的标准治疗方式.随着化放疗技术的快速发展,术前化放疗、术后化放疗、化放疗联合术中放疗等各种化放疗方案不断地被业内学者所报道.本综述总结近年来报道的关于胃癌患者手术前后的辅助性化放疗方案及其临床试验结果,并综合评价化放疗在可切除性胃癌中的治疗价值及意义.

Clinical research progression in chemoradiation therapy for resectable gastric cancer

In recent years, based on the phase III( clinical study, postoperative chemoradiation, perioperative chemotherapy with ECF regimen and postoperative adjuvant chemotherapy with oral S-1 have become the standard adjuvant treatment of resectable gastric adenocarcinoma in the United States, Europe, and Japan, respectively. Since the Southwest Oncology Group in 2001 reported a large phase III( randomized clinical trial INT0116, adjuvant chemoradiotherapy has become a standard treatment for gastric adenocarcinoma. With the rapid development of chemoradiotherapy technique, clinical researches for using operation combined with chemoradiotherapy to treat gastric adenocarcinoma emerged one after another, including adjuvant postoperative chemoradiation, preoperative chemoradiation, and chemoradiation combined with intraoperative radiotherapy and so on. This review will summarize the recent treatment protocol using chemoradiotherapy for resectable gastric adenocarcinoma, and comprehensively evaluate the clinical value and significance of chemoradiotherapy for resectable gastric adenocarcinoma.